You are about to leave a GSK website

Third party content disclaimers

 

You are about to leave a GSK website. By clicking this link, you will be taken to a website that is independently operated and not managed by GSK. The website you are linking to is not controlled or endorsed by GSK and GSK assumes no responsibility for the content on the website. If you wish to proceed, click "OK". If you do not wish to leave this website, click “CANCEL”.

OK

CANCEL

nucala docquity webinar nucala docquity webinar

Join us for Advances in CRSwNP and Severe Asthma: The Role of Mepolizumab, webinar featuring Dr. Png Lu Hui, Consultant ENT Surgeon, Singapore General Hospital.

This webinar highlights the role of biologic therapy in the management of chronic rhinosinusitis with nasal polyps (CRSwNP) and severe eosinophilic asthma, with a focus on the clinical application of mepolizumab. Gain expert insights on patient phenotyping, treatment selection, and strategies to optimise outcomes across ENT and respiratory care.

Calendar Icon


Aug 27, Wednesday | 7:00 - 8:00 pm

Calendar Icon

Aug 27, Wednesday | 7:00 - 8:00 pm

Watch recording here

Nucala (mepolizumab) Safety Information:1

Contraindications:
Hypersensitivity to mepolizumab or to any of the excipients.

Warnings and Precautions:
NUCALA should not be used to treat acute asthma exacerbations.

Very common (≥1/10) adverse reactions include headache and some common (≥1/100 to <1/10) adverse reactions include pharyngitis, lower respiratory tract infection and urinary tract infection. 

Before prescribing, please refer to the full prescribing information available here.

Abbreviations:

CRSwNP: chronic rhinosinusitis with nasal polyps; ENT: ear nose and throat.

Reference:

  1. Nucala Prescribing Information.

Trade marks are owned by or licensed to the GSK group of companies.

PM-MY-MPL-WCNT-250002 10/25